-

SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Examining Potential Securities Law Violations at aTyr Pharma

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In aTyr To Contact Him Directly To Discuss Their Options

If you suffered losses in aTyr and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

NEW YORK--(BUSINESS WIRE)--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against aTyr Pharma, Inc. (“aTyr” or the “Company”) (NASDAQ: ATYR).

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

On Monday, September 15, 2025, aTyr Pharma, Inc. announced before the market opened that its EFZO-FIT study failed to meet its primary endpoint—the change from baseline in mean daily oral corticosteroid (OSC) dose at week 48—during an investor call.

The disappointing topline results triggered a sharp and immediate market sell-off. aTyr’s stock, which had closed at $6.03 per share on Friday, September 12, plunged to $1.02 per share by the close of trading on September 15, marking a single-day decline of approximately 83.2%.

To learn more about the ATyr Pharma investigation, go to www.faruqilaw.com/ATYR or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

Contacts

Faruqi & Faruqi, LLP
Josh Wilson
877-247-4292 or 212-983-9330 (Ext. 1310)

More News From Faruqi & Faruqi, LLP

ARDELYX (NASDAQ: ARDX) CLASS ACTION DEADLINE TODAY: Faruqi & Faruqi, LLP Reminds Investors of November 16, 2026 Lead Plaintiff Deadline

NEW YORK--(BUSINESS WIRE)--Faruqi & Faruqi, LLP reminds investors in Ardelyx, Inc. (“Ardelyx” or the “Company”) (NASDAQ: ARDX) of the November 16, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. The firm is also investigating potential claims against Ardelyx. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundred...

APPLOVIN (NASDAQ: APP) CLASS ACTION DEADLINE TODAY: Faruqi & Faruqi, LLP Reminds Investors of November 16, 2026 Lead Plaintiff Deadline

NEW YORK--(BUSINESS WIRE)--Faruqi & Faruqi, LLP reminds investors in AppLovin Corporation (“AppLovin” or the “Company”) (NASDAQ: APP) of the November 16, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. The firm is also investigating potential claims against AppLovin. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered...

BIDU CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Baidu (NASDAQ: BIDU) Investors of Securities Class Action Lawsuit Deadline on November 13, 2026

NEW YORK--(BUSINESS WIRE)--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Baidu, Inc. (“Baidu” or the “Company”) (NASDAQ: BIDU) and reminds investors of the November 13, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has reco...
Back to Newsroom